Ernexa Therapeutics (ERNAW) Income towards Parent Company (2010 - 2026)

Ernexa Therapeutics has reported Income towards Parent Company for 17 years, with the latest figure at -$5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 32.87% year-over-year to -$5.5 million; the trailing twelve-month figure through Mar 2026 stood at -$11.4 million (down 643.5% YoY), and the FY2025 full-year result was -$14.1 million, down 83229.41% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$5.5 million, down from -$1.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was $38.8 million in Q4 2024, with the low at -$26.6 million in Q3 2024.
• Historically, Income towards Parent Company has averaged -$3.9 million across 5 years, with a median of -$5.5 million in 2026.
• The largest YoY upside for Income towards Parent Company was 732.28% in 2024 against a maximum downside of 375.84% in 2024.
• Ernexa Therapeutics' Income towards Parent Company stood at -$4.4 million in 2022, then sank by 37.95% to -$6.1 million in 2023, then surged by 732.28% to $38.8 million in 2024, then tumbled by 104.0% to -$1.5 million in 2025, then plunged by 255.23% to -$5.5 million in 2026.
• The last three Income towards Parent Company figures came in at -$5.5 million (Q1 2026), -$1.5 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.